



**Company Contact:**  
**Richard Gabriel**  
**CEO and President**  
**941 366-3400**

**-or-**

**Ron Stabiner**  
**The Wall Street Group, Inc.**  
**212-888-4848**

**FOR IMMEDIATE RELEASE:**

**DNAPRINT GENOMICS TO DISCUSS SECOND QUARTER RESULTS AND  
PROVIDE UPDATE ON CURRENT ACTIVITIES VIA LIVE WEBCAST**

**SARASOTA, Fla., Aug. 14, 2006 – DNAPrint Genomics, Inc. (OTCBB: DNAG)** today announced that the Company's senior management will discuss results for the second quarter of 2006, and provide an update on related activities and the status of its projects via a live Webcast, on Tuesday, August 22, at 2:00 PM Eastern time.

Richard Gabriel, President and Chief Executive Officer, and Hector J. Gomez, M.D., Ph.D., Chief Medical Officer and Chairman of the Board, will provide an overview of the company and its projects. Karen Surplus, Chief Financial Officer, will review the financial results. They will be available to take questions via email following the presentation.

To access the live Webcast, interested parties are asked to register at <http://brighttalk.com/event/DNAPrint/e2ef524fbf-97-intro>, and then complete the form, at which time detailed information for accessing the Webcast will be provided. The live Webcast will also be archived and accessed free of charge at <http://brighttalk.com/event/DNAPrint/e2ef524fbf-97-intro> for 45 days.

**About DNAPrint Genomics, Inc.**

DNAPrint Genomics, Inc. ([www.dnaprint.com](http://www.dnaprint.com)) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to [www.dnaprint.com](http://www.dnaprint.com) for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

(MORE)

**Forward-Looking Statements**

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

##